Lizza Named to NJBIZ Law Power Top 50 List
Charles M. Lizza, Vice Chair of Saul Ewing Arnstein & Lehr’s Litigation Department and Chair of its Life Sciences & IP Litigation Practice, was named to the NJBIZ Law Power Top 50 list. The publication selected professionals for the list based on the results they have achieved in the state. It said, "the professionals recognized in these pages all help set the agenda for New Jersey. And they get results… [T]he Power 50 lawyers likely have a lot of satisfied clients and constituents. It’s safe to say that the entire state benefits from the high quality of work turned in by the attorneys on this list. … By performing at a high level, these professionals force their adversaries to do the same. That’s good for everyone who cares about making New Jersey a better place to live, work and do business."
Charlie’s profile recognizes that "the pharmaceutical industry is a huge segment of the New Jersey economy and Lizza helps those drugmakers protect one of their most valuable resources: intellectual property." Charlie has handled cases for dozens of major pharmaceutical companies. Examples of his work include representing Celgene Corp. in defending its Revlimid drug, a treatment for multiple myeloma and blood disorders, which produces annual sales of about $6 billion. He also represented Johnson & Johnson’s DePuy subsidiary in a patent suit involving Stryker over medical devices with sales of about $200 million. Among many activities, he serves on the U.S. District Court’s New Jersey Local Patent Rules Committee and has served as a mediator in the Southern District of New York since 1992.